Abivax S.A.
ABVX
Rangering i aksjer
#2371
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Aksjekurs
$92.14
Markedsverdi
$8.04B
Endring (1 dag)
-2.73%
Endring (1 år)
4.27%
Land
FR
Handel Abivax S.A. (ABVX)
Kategori
Healthcare
Aksjeprishistorikk for Abivax S.A. (ABVX)
Høyeste sluttskurs: $94.68 den 2026-10-01
Laveste sluttskurs: $23.10 den 2015-06-01
Laveste sluttskurs: $23.10 den 2015-06-01
Aksjeprishistorikk for Abivax S.A. fra 2015 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -6.04% |
| 2025 | 1,503.20% |
| 2024 | -26.43% |
| 2023 | 60.28% |
| 2022 | -77.75% |
| 2021 | -2.30% |
| 2020 | 54.91% |
| 2019 | 56.94% |
| 2018 | 22.67% |
| 2017 | 47.19% |
| 2016 | -57.07% |
| 2015 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.73 | 25.86% |
US
|
|
| $225.94 | 741.49% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.85 | 7.94% |
NL
|
